Welcome to our dedicated page for NEWCELX SEC filings (Ticker: NLSPW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The NLSPW SEC filings page provides access to regulatory documents that reference the warrants of NLS Pharmaceutics Ltd. and the broader capital structure of the company. As a foreign private issuer, NLS Pharmaceutics files an annual report on Form 20-F and frequent current reports on Form 6-K with the U.S. Securities and Exchange Commission, and these filings often describe transactions that involve warrants, preferred securities, and equity facilities.
For NLSPW, the most relevant filings include Form 6-K reports detailing private placement financings, warrant issuances, warrant exchanges, and pre-funded warrant arrangements. For example, the company has reported securities purchase agreements for preferred shares and preferred participation certificates, associated common share purchase warrants, and a warrant exchange agreement in which an existing warrant was exchanged for common shares under Section 3(a)(9) of the Securities Act. These documents explain how warrants fit into NLS Pharmaceutics’ financing strategy and how they may be adjusted in connection with corporate events.
Filings related to the merger with Kadimastem Ltd. are also important for understanding NLSPW. Through a registration statement on Form F-4 and multiple Form 6-K amendments, NLS Pharmaceutics has disclosed the terms of the Agreement and Plan of Merger, extensions of the termination date, changes to the exchange ratio calculation, and shareholder approvals. Company communications state that, following the merger and reverse share split, the combined company will be named NewCelX Ltd. and listed on Nasdaq under the symbol NCEL, and that currently traded warrants will not be listed for trading post-merger.
On Stock Titan, AI-powered tools can help summarize these filings so readers can quickly see how warrant terms, equity financings, and merger mechanics are described in official documents. Users can review Form 6-K reports for financing and merger updates, the Form F-4 for detailed transaction terms, and the Form 20-F for broader risk factor and capital structure discussions that provide context for NLSPW.
NewcelX Ltd. announced a private placement financing with accredited investors, selling 490,907 common shares (or pre-funded warrants) at $2.75 per share, a 30% premium to the prior closing price, and issuing common warrants to purchase up to 687,270 shares at an exercise price of $3.025 per share.
The transaction is expected to provide gross proceeds of $1.35 million, with an additional approximately $2.1 million possible from full cash exercise of the warrants. NewcelX plans to use the proceeds, alongside its previously announced $25 million equity line, to advance NCEL-101, its lead stem-cell-based therapy program for Type 1 Diabetes, as well as other pipeline programs, working capital and general corporate purposes.
The offering is expected to close on or about April 15, 2026, subject to customary closing conditions, and the securities are being issued under Section 4(a)(2) and Rule 506(b) of Regulation D, with a commitment to file a resale registration statement for the underlying shares.
NewcelX Ltd. filed a current report describing that it has issued a press release announcing a strategic collaboration with Eledon Pharmaceuticals to advance its NCEL-101 program targeting Type 1 diabetes. The report also states that the first four paragraphs of this press release are incorporated by reference into several existing NewcelX shelf registration statements on Form F-3.
NewcelX Ltd. reported a peer-reviewed scientific review of Mazindol Immediate-Release/Sustained-Release (IR/SR) published in Clinical Drug Investigation. The company views this publication as independent validation of Mazindol ER’s clinical and mechanistic profile within its Contingent Value Right (CVR) framework.
NewcelX stated it is in advanced discussions with multiple potential partners on licensing or acquisition transactions for Mazindol ER, aiming to optimize terms and enhance value for CVR holders and shareholders. The company highlights over 20 years of research and intellectual property dating back to 2006, positioning Mazindol ER as a differentiated central nervous system asset targeting narcolepsy, ADHD, and substance use disorders.
NewcelX Ltd. furnished a 6-K announcing an updated corporate presentation and investor deck ahead of key spring 2026 investor and partnering conferences, including BIO-Europe Spring in Lisbon. The materials emphasize NewcelX’s primary focus on cell-based therapies for Type 1 Diabetes and its broader platform in metabolic and neurodegenerative diseases.
The updated presentation highlights recent scientific progress, clinical development priorities, and the company’s approach to restoring endogenous insulin production using regenerative medicine. It also introduces several new, internationally recognized members of the Scientific Advisory Board and leadership team, which NewcelX states will strengthen expertise across cell therapy development, translational medicine, clinical strategy, and commercialization.
NLS Pharmaceutics Ltd. is changing its independent auditor because CBIZ CPAs P.C. acquired the attestation business of Marcum LLP. Marcum resigned effective September 17, 2025, and CBIZ was engaged the same day as the independent registered public accounting firm for the fiscal year ending December 31, 2025, with Audit Committee approval.
Marcum’s report on the December 31, 2024 financial statements was unqualified but included an explanatory paragraph about substantial doubt regarding the Company’s ability to continue as a going concern. The Company reports no disagreements with Marcum on accounting or auditing matters and, apart from previously disclosed material weaknesses in internal control over financial reporting, no additional reportable events. The Company also states it did not consult CBIZ on accounting or auditing issues before this engagement.
NLS Pharmaceutics Ltd. furnished a report stating that on September 10, 2025 it issued a press release titled “Kadimastem and NLS Pharmaceutics Announce Effectiveness of SEC Registration Statement in Connection with Proposed Merger.” The report indicates that a related SEC registration statement for the proposed merger between NLS Pharmaceutics and Kadimastem has become effective, and the press release describing this development is attached as Exhibit 99.1.
NLS Pharmaceutics Ltd. furnished a report describing a new press release issued on September 4, 2025. The press release announces that NLS Pharmaceutics and Kadimastem have a Hong Kong patent covering a cell-selection and enrichment technology for IsletRx, a treatment approach aimed at diabetes patients. The 6-K mainly serves to provide this press release to investors as Exhibit 99.1.
NLS Pharmaceutics Ltd. filed a Form 6-K to report that it entered into a seventh amendment to its Agreement and Plan of Merger with Kadimastem Ltd. and NLS Pharmaceutics (Israel) Ltd. The amendment extends the merger agreement’s termination date from August 31, 2025 to October 31, 2025 to allow more time to complete the merger.
The extension is intended to provide additional time for NLS Pharmaceutics to receive and evaluate further comments from the U.S. Securities and Exchange Commission on its pending Form F-4 registration statement for the proposed merger transaction with Kadimastem. The parties state that they remain focused on and committed to completing the merger and are working to satisfy all regulatory and closing requirements.
NLS Pharmaceutics Ltd. has postponed its Extraordinary Shareholders’ Meeting, originally planned for August 25, 2025, to September 16, 2025. The meeting is intended to approve transactions related to the company’s contemplated merger with Kadimastem Ltd.
The delay is meant to give NLS Pharmaceutics more time to receive and review additional comments from the U.S. Securities and Exchange Commission on its pending Form F-4 registration statement and to ensure shareholders receive the most current and complete information before voting. The meeting may be postponed again, and any further changes will be announced via another Form 6-K and a notice to shareholders. No action is required from shareholders at this time.